Skip to main content
. 2021 May 22;394(8):1713–1725. doi: 10.1007/s00210-021-02100-7

Table 3.

Relative risk for the rapid progression of CAC with either the DM GRS/the individual SNPs alone as risk factors or the interaction between HMGRI intake and the DM GRS/SNPs as risk factors

Genetic risk score/SNP Chr Base position Gene Risk/other allele RAF HWE Model 1:
Rapid progression of CAC = DM GRS/SNP + age + sex + log(CACb + 1)
Model 3:
Rapid progression of CAC = DM GRS/SNP + age + sex + log(CACb + 1) + HMGRI intake + DM GRS/SNP × HMGRI
RR [95% CI], p RR [95% CI], p
Diabetes mellitus genetic risk score 1.01 [0.94; 1.10], 0.73 1.08 [0.83; 1.41], 0.56
rs17106184 1 50,909,985 FAF1 G/A 0.91 1 1.13 [0.92; 1.39], 0.25 0.88 [0.45; 1.75], 0.72
rs10923931 1 120,517,959 NOTCH2 T/G 0.10 0.63 0.97 [0.80; 1.17], 0.71 1.06 [0.57; 1.96], 0.86
rs2075423 1 214,154,719 PROX1 G/T 0.63 0.82 0.97 [0.87; 1.09], 0.67 1.18 [0.81; 1.72], 0.40
rs2867125 2 622,827 TMEM18 C/T 0.82 0.95 1.10 [0.94; 1.28], 0.25 0.78 [0.49; 1.26], 0.31
rs780094 2 27,741,237 GCKR C/T 0.60 0.26 0.99 [0.88; 1.11], 0.87 1.27 [0.88; 1.83], 0.20
rs10203174 2 43,690,030 THADA C/T 0.88 0.73 0.84 [0.72; 0.99], 0.04 1.23 [0.67; 2.26], 0.51
rs243088 2 60,568,745 BCL11A T/A 0.46 0.20 0.99 [0.89; 1.11], 0.90 1.17 [0.83; 1.66], 0.36
rs11123406 2 111,950,541 BCL2L11 T/C 0.35 0.17 1.04 [0.92; 1.18], 0.55 0.99 [0.68; 1.45], 0.96
rs998451 2 135,429,288 TMEM163 A/G 0.41 0.14 1.00 [0.90; 1.12], 0.94 1.15 [0.80; 1.65], 0.45
rs4410242 2 161,192,070 RBMS1 G/A 0.81 0.69 0.99 [0.86; 1.14], 0.84 1.10 [0.70; 1.73], 0.68
rs3923113 2 165,501,849 GRB14 A/C 0.61 0.76 0.92 [0.82; 1.04], 0.18 0.96 [0.66; 1.40], 0.85
rs2943640 2 227,093,585 IRS1 C/A 0.64 0.21 1.00 [0.89; 1.12], 0.97 1.15 [0.79; 1.67], 0.46
rs1801282 3 12,393,125 PPARG C/G 0.86 0.27 1.01 [0.87; 1.19], 0.85 0.86 [0.54; 1.36], 0.51
rs7612463 3 23,336,450 UBE2E2 C/A 0.90 0.84 1.09 [0.90; 1.33], 0.38 0.66 [0.37; 1.16], 0.15
rs831571 3 64,048,297 PSMD6 C/T 0.82 0.76 0.96 [0.83; 1.12], 0.63 1.32 [0.80; 2.18], 0.28
rs6795735 3 64,705,365 ADAMTS9 C/T 0.59 0.79 1.02 [0.91; 1.14], 0.78 1.30 [0.89; 1.91], 0.18
rs11717195 3 123,082,398 ADCY5 T/C 0.78 0.84 0.94 [0.83; 1.08], 0.41 1.04 [0.68; 1.59], 0.85
rs4402960 3 185,511,687 IGF2BP2 T/G 0.31 0.29 1.02 [0.90; 1.15], 0.76 1.15 [0.78; 1.71], 0.48
rs16861329 3 186,666,461 ST64GAL1 C/T 0.87 0.42 1.08 [0.90; 1.28], 0.42 0.96 [0.56; 1.65], 0.89
rs6808574 3 187,740,523 LPP C/T 0.61 0.48 1.07 [0.99; 1.21], 0.27 0.74 [0.51; 1.09], 0.12
rs4458523 4 6,289,986 WFS1 G/T 0.60 0.88 1.06 [0.94; 1.18], 0.36 1.11 [0.77; 1.58], 0.58
rs7674212 4 103,988,899 CISD2 G/T 0.58 0.79 0.89 [0.79; 1.00], 0.04 1.22 [0.85; 1.78], 0.28
rs2706785 4 122,660,250 TMEM155 G/A 0.03 0.12 0.75 [0.51; 1.10], 0.14 1.37 [0.40; 4.69], 0.62
rs6813195 4 153,520,475 TMEM154 C/T 0.73 1 1.00 [0.88; 1.14], 0.96 0.89 [0.58; 1.36], 0.60
rs1996546 4 185,714,289 ACSL1 G/T 0.85 0.24 0.98 [0.83; 1.14], 0.76 1.52 [0.88; 2.61], 0.13
rs702634 5 53,271,420 ARL15 A/G 0.68 0.16 1.00 [0.89; 1.13], 0.96 0.97 [0.66; 1.43], 0.87
rs459193 5 55,806,751 ANKRD55 G/A 0.74 0.55 1.07 [0.94; 1.21], 0.32 0.95 [0.61; 1.48], 0.82
rs6878122 5 76,427,311 ZBED3 G/A 0.29 0.72 0.98 [0.86; 1.11], 0.74 0.66 [0.42; 1.02], 0.06
rs329122 5 133,864,599 PHF15 A/G 0.40 0.88 1.00 [0.89; 1.12], 0.95 0.83 [0.56; 1.23], 0.35
rs9505118 6 7,290,437 SSR1/RREB1 A/G 0.60 0.19 1.02 [0.91; 1.14], 0.71 1.06 [0.74; 1.51], 0.75
rs7756992 6 20,679,709 CDKAL1 G/A 0.29 0.40 1.00 [0.88; 1.13], 0.98 0.82 [0.53; 1.29], 0.40
rs3130501 6 31,136,453 POU5F1/TCF19 G/A 0.73 0.03 0.95 [0.84; 1.08], 0.45 0.97 [0.66; 1.44], 0.89
rs2050188 6 32,339,897 HLA-DRB5 T/C 0.63 0.81 0.99 [0.88; 1.12], 0.88 1.02 [0.69; 1.50], 0.92
rs9271775 6 32,594,328 HLA-DQA1 T/C 0.82 0.14 1.04 [0.90; 1.21], 0.57 1.49 [0.85; 2.59], 0.16
rs9470794 6 38,106,844 ZFAND3 T/C 0.92 0.53 1.16 [0.92; 1.46], 0.21 0.50 [0.28; 0.92], 0.02
rs4407733 6 137,299,152 IL20RA A/G 0.53 0.91 0.94 [0.84; 1.05], 0.24 1.30 [0.91; 1.85], 0.15
rs622217 6 160,766,770 SLC22A3 T/C 0.47 0.50 1.04 [0.93; 1.16], 0.54 1.06 [0.75; 1.49], 0.76
rs17168486 7 14,898,282 DGKB T/C 0.18 0.95 0.90 [0.77; 1.04], 0.16 1.03 [0.62; 1.69], 0.91
rs849135 7 28,196,413 JAZF1 G/A 0.50 0.86 1.06 [0.94; 1.18], 0.34 0.98 [0.69; 1.38], 0.89
rs10278336 7 44,245,363 GCK A/G 0.58 0.26 1.11 [0.99; 1.24], 0.08 1.09 [0.75; 1.60], 0.64
rs6467136 7 127,164,958 GCC1 A/G 0.46 0.46 1.01 [0.90; 1.13], 0.87 1.13 [0.77; 1.64], 0.54
rs13233731 7 130,437,689 KLF14 G/A 0.51 0.22 1.04 [0.93; 1.16], 0.53 1.09 [0.77; 1.55], 0.63
rs9648716 7 140,612,163 BRAF T/A 0.14 0.94 1.02 [0.87; 1.20], 0.80 0.97 [0.59; 1.60], 0.92
rs1182397 7 157,031,407 MNX1 G/T 0.84 0.69 1.00 [0.85; 1.16], 0.97 0.81 [0.48; 1.34], 0.41
rs12681990 8 36,859,186 KCNU1 C/T 0.19 0.55 0.97 [0.84; 1.13], 0.71 0.82 [0.49; 1.39], 0.47
rs516946 8 41,519,248 ANK1 C/T 0.76 0.03 1.04 [0.91; 1.18], 0.55 1.44 [0.91; 2.28], 0.12
rs7845219 8 95,937,502 TP53INP1 T/C 0.54 0.94 1.02 [0.91; 1.14], 0.75 0.96 [0.67; 1.37], 0.83
rs3802177 8 118,185,025 SLC30A8 G/A 0.69 0.55 1.04 [0.92; 1.18], 0.49 1.21 [0.81; 1.81], 0.36
rs7041847 9 4,287,466 GLIS3 A/G 0.51 0.45 0.91 [0.80; 1.01], 0.08 0.81 [0.56; 1.17], 0.27
rs17584499 9 8,879,118 PTPRD T/C 0.20 0.43 1.09 [0.95; 1.26], 0.21 1.53 [0.96; 2.44], 0.07
rs10811661 9 22,134,094 CDKN2A/B T/C 0.83 0.61 1.08 [0.92; 1.25], 0.34 1.02 [0.61; 1.70], 0.94
rs17791513 9 81,905,590 TLE4 A/G 0.93 0.56 1.07 [0.85; 1.36], 0.56 0.90 [0.44; 1.84], 0.76
rs2796441 9 84,308,948 TLE1 G/A 0.60 0.47 1.01 [0.90; 1.13], 0.92 0.96 [0.67; 1.40], 0.85
rs495828 9 136,154,867 ABO T/G 0.24 0.003 0.92 [0.80; 1.05], 0.21 0.89 [0.57; 1.38], 0.59
rs11257655 10 12,307,894 CDC123 T/C 0.21 0.41 0.95 [0.83; 1.10], 0.52 0.80 [0.50; 1.28], 0.36
rs1802295 10 70,931,474 VPS26A T/C 0.32 0.02 1.01 [0.90; 1.13], 0.88 0.97 [0.67; 1.42], 0.89
rs12571751 10 80,942,631 ZMIZ1 A/G 0.53 0.11 0.99 [0.88; 1.10], 0.79 0.95 [0.66; 1.38], 0.80
rs1111875 10 94,462,882 HHEX/IDE C/T 0.59 0.88 0.98 [0.88; 1.10], 0.77 1.14 [0.79; 1.66], 0.49
rs7903146 10 114,758,349 TCF7L2 T/C 0.28 0.89 0.93 [0.82; 1.06], 0.27 0.77 [0.51; 1.18], 0.22
rs10886471 10 121,149,403 GRK5 T/C 0.45 0.48 1.02 [0.90; 1.14], 0.78 0.68 [0.46; 1.01], 0.05
rs2421016 10 124,167,512 PLEKHA1 C/T 0.50 0.61 0.89 [0.80; 1.00], 0.06 1.03 [0.72; 1.48], 0.87
rs2334499 11 1,696,849 DUSP8 T/C 0.40 0.82 1.04 [0.93; 1.16], 0.48 1.09 [0.77; 1.55], 0.61
rs163184 11 2,847,069 KCNQ1 G/T 0.50 0.72 0.98 [0.88; 1.10], 0.74 1.11 [0.78; 1.60], 0.55
rs5215 11 17,408,630 KCNJ11 C/T 0.36 0.51 1.03 [0.92; 1.16], 0.62 1.01 [0.70; 1.45], 0.95
rs3736505 11 43,876,435 HSD17B12 G/A 0.30 0.25 1.00 [0.88; 1.13], 0.98 1.00 [0.68; 1.48], 0.99
rs11227234 11 65,365,171 MAP3K11 T/G 0.24 0.11 1.01 [0.88; 1.15], 0.88 1.27 [0.84; 1.92], 0.26
rs1552224 11 72,433,098 ARAP1 (CENTD2) A/C 0.84 0.79 0.78 [0.68; 0.90], 0.001 0.94 [0.60; 1.47], 0.80
rs10830963 11 92,708,710 MTNR1B G/C 0.29 0.36 1.09 [0.96; 1.23], 0.19 1.04 [0.72; 1.51], 0.84
rs11063069 12 4,374,373 CCND2 G/A 0.21 0.79 1.04 [0.90; 1.19], 0.61 1.00 [0.65; 1.56], 0.99
rs10842994 12 27,965,150 KLHDC5 C/T 0.79 0.48 0.97 [0.85; 1.11], 0.67 0.56 [0.34; 0.91], 0.02
rs2261181 12 66,212,318 HMGA2 T/C 0.09 0.51 1.00 [0.82; 1.22], 0.99 0.69 [0.35; 1.39], 0.30
rs7955901 12 71,433,293 TSPAN8 C/T 0.45 0.36 1.06 [0.95; 1.19], 0.31 0.75 [0.52; 1.09], 0.13
rs12427353 12 121,426,901 HNF1B G/C 0.82 0.81 0.99 [0.86; 1.18], 0.91 0.82 [0.52; 1.29], 0.38
rs1727294 12 123,616,514 MPHOSPH9 G/A 0.79 0.87 0.92 [0.80; 1.05], 0.20 1.16 [0.75; 1.79], 0.50
rs825476 12 124,568,456 CCDC92 T/C 0.57 0.71 1.06 [0.94; 1.19], 0.31 1.00 [0.69; 1.43], 0.99
rs10507349 13 26,781,528 RNF6 G/A 0.77 0.32 0.92 [0.81; 1.06], 0.25 1.00 [0.65; 1.55], 0.99
rs576674 13 33,554,302 KL G/A 0.17 0.79 0.98 [0.84; 1.14], 0.78 0.79 [0.46; 1.32], 0.35
rs1359790 13 80,717,156 SPRY2 G/A 0.72 1 1.02 [0.90; 1.16], 0.73 0.98 [0.66; 1.47], 0.93
rs7985179 13 91,940,169 MIR17HG T/A 0.75 0.52 0.91 [0.80; 1.04], 0.17 1.06 [0.69; 1.63], 0.78
rs17109256 14 79,939,993 NRXN3 A/G 0.22 0.50 0.97 [0.85; 1.11], 0.67 1.41 [0.93; 2.13], 0.10
rs7403531 15 38,822,905 RASGRP1 T/C 0.21 0.44 1.05 [0.90; 1.20], 0.54 1.07 [0.70; 1.63], 0.77
rs4502156 15 62,383,155 C2CD4A C/T 0.41 0.88 0.92 [0.82; 1.03], 0.14 1.18 [0.81; 1.73], 0.39
rs7178572 15 77,747,190 HMG20A G/A 0.70 1 1.04 [0.92; 1.18], 0.53 0.91 [0.61; 1.36], 0.66
rs11634397 15 80,432,222 ZFAND6 G/A 0.68 0.65 0.96 [0.85; 1.08], 0.53 0.93 [0.64; 1.37], 0.72
rs2028299 15 90,374,257 AP3S2 C/A 0.28 0.78 1.02 [0.89; 1.15], 0.82 1.02 [0.67; 1.54], 0.94
rs12899811 15 91,544,076 PRC1 G/A 0.31 0.97 1.04 [0.92; 1.17], 0.54 0.81 [0.54; 1.20], 0.29
rs9940149 16 300,641 ITFG3 G/A 0.81 0.11 0.87 [0.75; 1.00], 0.05 1.34 [0.83; 2.16], 0.24
rs9936385 16 53,819,169 FTO C/T 0.41 0.88 0.94 [0.84; 1.06], 0.31 1.09 [0.77; 1.55], 0.61
rs7202877 16 75,247,245 BCAR1 T/G 0.89 0.71 0.92 [0.77; 1.10], 0.37 0.97 [0.54; 1.73], 0.91
rs2925979 16 81,534,790 CMIP T/C 0.30 0.67 1.03 [0.91; 1.17], 0.60 1.22 [0.84; 1.79], 0.30
rs391300 17 2,216,258 SRR C/T 0.64 0.67 1.02 [0.91; 1.14], 0.77 0.87 [0.59; 1.29], 0.48
rs8068804 17 3,985,864 ZZEF1 A/G 0.32 0.07 1.01 [0.89; 1.13], 0.93 1.45 [1.01; 2.09], 0.04
rs17676067 17 9,791,375 GLP2R C/T 0.28 0.12 0.98 [0.86; 1.10], 0.70 1.27 [0.89; 1.81], 0.18
rs11651052 17 36,102,381 HNF1B G/A 0.53 0.33 1.07 [0.96; 1.20], 0.21 0.94 [0.66; 1.34], 0.74
rs15563 17 47,005,193 GIP G/A 0.53 0.61 1.04 [0.93; 1.16], 0.53 1.00 [0.71; 1.40], 0.98
rs12970134 18 57,884,750 MC4R A/G 0.26 0.82 0.94 [0.83; 1.07], 0.39 1.37 [0.92; 2.06], 0.12
rs10401969 19 19,407,718 CILP2 C/T 0.08 0.52 1.22 [1.00; 1.48], 0.04 1.21 [0.63; 2.34], 0.57
rs3786897 19 33,893,008 PEPD A/G 0.58 0.24 0.95 [0.85; 1.06], 0.33 0.99 [0.69; 1.43], 0.96
rs8108269 19 46,158,513 GIPR G/T 0.31 0.70 0.93 [0.83; 1.06], 0.28 0.78 [0.51; 1.19], 0.25
rs4812829 20 42,989,267 HNF4A A/G 0.18 0.67 1.02 [0.88; 1.19], 0.75 1.04 [0.66; 1.62], 0.87

Chr chromosome, Gene specify the nearby gene, RAF risk allele frequency, HWE Hardy–Weinberg equilibrium, CACb coronary artery calcification score at baseline. The model is adjusted for age, sex, and log(CACb + 1) and consists of the interaction between GRS/SNP × HMGRI intake.